These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19557469)

  • 41. Re: Adjuvant Cisplatin-Based Combined Chemotherapy for Lymph Node (LN)-Positive Urothelial Carcinoma of the Bladder (UCB) after Radical Cystectomy (RC): A Retrospective International Study of >1500 Patients.
    Chang SS
    J Urol; 2016 Feb; 195(2):300. PubMed ID: 26852970
    [No Abstract]   [Full Text] [Related]  

  • 42. [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].
    Schmid SC; Gschwend JE; Retz M;
    Aktuelle Urol; 2014 Jan; 45(1):55-63; quiz 64-5. PubMed ID: 24500963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Systemic chemotherapy of urothelial carcinoma].
    Wolff J; Jakse G
    Urologe A; 1991 Jan; 30(1):25-32. PubMed ID: 2014584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bladder cancer: management of advanced disease.
    Chong CD
    Tex Med; 1987 Feb; 83(2):51-4. PubMed ID: 3824246
    [No Abstract]   [Full Text] [Related]  

  • 45. Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation.
    Clark PE
    Urol Oncol; 2015 Oct; 33(10):434-6. PubMed ID: 26278365
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer.
    Gust KM; Rebhan K; Resch I; Shariat SF; Necchi A
    Curr Opin Urol; 2020 Jul; 30(4):547-556. PubMed ID: 32453001
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeted therapy in advanced urothelial carcinoma.
    Verdoorn BP; Kessler ER; Flaig TW
    Oncology (Williston Park); 2013 Mar; 27(3):219-26. PubMed ID: 23687793
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy for invasive bladder cancer.
    Malkowicz SB; Vaughn DJ
    Urology; 1996 Apr; 47(4):602-14. PubMed ID: 8638379
    [No Abstract]   [Full Text] [Related]  

  • 49. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.
    Porter MP; Kerrigan MC; Donato BM; Ramsey SD
    Urol Oncol; 2011; 29(3):252-8. PubMed ID: 19450992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
    Wood DP
    J Urol; 2013 Dec; 190(6):2019. PubMed ID: 24209516
    [No Abstract]   [Full Text] [Related]  

  • 51. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
    Bellmunt J; Hussain M; Dinney CP
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Chemotherapy of invasive bladder cancer].
    Kotake T
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
    Culine S
    Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527
    [No Abstract]   [Full Text] [Related]  

  • 54. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium.
    Sonpavde G; Sternberg CN; Rosenberg JE; Hahn NM; Galsky MD; Vogelzang NJ
    Lancet Oncol; 2010 Sep; 11(9):861-70. PubMed ID: 20537950
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systemic therapy of bladder cancer.
    Salem PA
    Prog Clin Biol Res; 1984; 162B():95-105. PubMed ID: 6209726
    [No Abstract]   [Full Text] [Related]  

  • 56. Bladder cancer: a review of clinical management and prognostic factors.
    Patel T; Pitman M; McKiernan JM
    Minerva Urol Nefrol; 2010 Dec; 62(4):377-86. PubMed ID: 20944539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on chemotherapy for advanced bladder cancer.
    Rosenberg JE; Carroll PR; Small EJ
    J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")].
    Heck MM; Gschwend JE; Retz M; ;
    Urologe A; 2012 Jun; 51(6):829-36. PubMed ID: 22526172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic chemotherapy in regionally advanced bladder cancer. Theoretical considerations and results.
    Scher HI
    Urol Clin North Am; 1992 Nov; 19(4):747-59. PubMed ID: 1441029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.